2,6-Dimethyl-6-anilino-symm.-triazin | 30360-35-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,6-Dimethyl-6-anilino-symm.-triazin
• 英文别名: (4,6-dimethyl-[1,3,5]triazin-2-yl)-phenyl-amine；4,6-dimethyl-N-phenyl-1,3,5-triazin-2-amine
• CAS: 30360-35-1
• 化学式: C₁₁H₁₂N₄
• 分子量: 200.243
• InChiKey: ZPECDWCFWFSWNM-UHFFFAOYSA-N

物化性质

• 沸点：
  401.3±28.0 °C(Predicted)
• 密度：
  1.194±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• INSECTICIDAL (1,3,5)-TRIAZINYL PHENYL HYDRAZONES
  申请人：Niyaz Noormohamed M.

  公开号：US20090093481A1

  公开（公告）日：2009-04-09

  (1,3,5)-Triazinyl phenyl hydrazones are effective at controlling insects.

  (1,3,5)-三嗪基苯基肼对控制昆虫有效。
• 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE
  申请人：Kubota Hideki

  公开号：US20080227785A1

  公开（公告）日：2008-09-18

  This invention relates to an anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient. It was proved that the BEC 1 potassium channel inhibitor has an action to improve learning disorder and is useful as a preventive or therapeutic agent for diseases, preferably dementia, in which the BEC 1 potassium channel is considered to be concerned. Illustratively, it was confirmed by an in vivo test that the BEC 1 potassium channel inhibitor has an action to improve learning disorder. Also, it was found that a compound having 2,4,6-triamino-1,3,5-triazine has a BEC 1 potassium channel inhibitory action.

  本发明涉及一种以BEC 1钾离子通道抑制剂作为活性成分的抗痴呆剂。已经证明，BEC 1钾离子通道抑制剂具有改善学习障碍的作用，并且作为预防或治疗剂是有用的，尤其是对于BEC 1钾离子通道与之相关的疾病，如痴呆症。例如，通过体内试验证实，BEC 1钾离子通道抑制剂具有改善学习障碍的作用。此外，还发现具有2,4,6-三氨基-1,3,5-三嗪的化合物具有BEC 1钾离子通道抑制作用。
• ORGANIC COMPOUNDS75074
  申请人：Fairhurst Robin Alec

  公开号：US20100105660A1

  公开（公告）日：2010-04-29

  A compound of formula (I), or tautomers, or stereoisomers, or solvates, or pharmaceutically acceptable salts thereof, wherein M 1 , M 2 , L 1 , L 2 , W 1 , W 2 , X 1 , X 2 , Y 1 , Y 2 , A, R 5 and R 5a are as defined herein for the for treatment of conditions treatable by the blockade of an epithelial sodium channel, particularly conditions benefiting from mucosal hydration.

  化合物式(I)的化合物，或其互变异构体、立体异构体、溶剂化物或药学上可接受的盐，其中M1、M2、L1、L2、W1、W2、X1、X2、Y1、Y2、A、R5和R5a的定义如本文所述，用于治疗可通过阻断上皮钠通道治疗的疾病，尤其是受益于粘膜水化的疾病。
• Epithelial sodium channel (ENaC) inhibitors
  申请人：Novartis AG

  公开号：EP2332933A1

  公开（公告）日：2011-06-15

  A compound of formula (I) or tautomers, or stereoisomers, or solvates, or pharmaceutically acceptable salts thereof, wherein M1, M2, L1, L2, W1, W2, X1, X2, Y1, Y2, A, R5 and R5a are as defined herein for the for treatment of conditions treatable by the blockade of an epithelial sodium channel, particularly conditions benefiting from mucosal hydration.

  式 (I) 的化合物 或其同分异构体、立体异构体、或其溶解物、或其药学上可接受的盐、 其中 M1、M2、L1、L2、W1、W2、X1、X2、Y1、Y2、A、R5 和 R5a 如本文所定义，用于治疗可通过阻断上皮钠通道治疗的疾病，特别是受益于粘膜水合作用的疾病。
• MIXTURES OF FIBRE REACTIVE DYES PRODUCTION AND USE THEREOF
  申请人：Giehl Andreas

  公开号：US20090041938A1

  公开（公告）日：2009-02-12

  The present invention concerns a dye mixture comprising at least one dye of the general formula (I) and at least one further dye either of the general formula (II) or of the general formula (III) or of the general formula (IV) where the variables are each as defined in claim 1, processes for their preparation and their use.